Europe reviews Valneva's chikungunya vaccine after reports of serious side effects
The European Medicines Agency's (EMA) safety committee has temporarily suspended the use of the vaccine, branded as Ixchiq, in adults aged 65 years and older.
The company said it will continue to monitor the reported events and cooperate with health authorities, while actively exploring a potential update to the vaccine's indication.
Ixchiq -- the first preventive shot against chikungunya virus to be authorized in the Europe as well as the U.S. -- contains a weakened strain of the virus that triggers the immune system to make antibodies.
The vaccine carries the risk of causing severe chikungunya-like adverse reactions, the EMA said in a statement.
Chikungunya is a mosquito-borne disease caused by the chikungunya virus. The most common symptoms of the infection are fever and joint pain.
About 17 serious adverse events, including two deaths, have been reported so far globally in people aged between 62 and 89 years who had received the vaccine, the agency said.
Two men aged 84 years and 77 years who had received the vaccine died in the French overseas territory of La Reunion, where a recent chikungunya outbreak has been reported.
The exact cause of the adverse events and their relationship with the vaccine have not yet been determined, the agency said, adding that the affected individuals also had other health conditions.
The French government suspended the use of the vaccine in persons aged 65 years and older last month pending investigation.
Advisers to the U.S. Centers for Disease Control and Prevention had recommended the vaccine last month for adults traveling to a country or territory where there is a chikungunya outbreak. The recommendation is yet to be signed off by the CDC.
(Reporting by Mariam Sunny in Bengaluru; Editing by Tasim Zahid and Shinjini Ganguli)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
Novo Nordisk shares dip further as Wegovy gains nearly erased
By Jacob Gronholt-Pedersen (Reuters) -Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent losses that threaten to wipe out all the gains since the drugmaker launched its blockbuster weight-loss treatment Wegovy four years ago. The fall on Friday means the Danish firm has dropped out of the top 10 constituents of the Europe-wide STOXX 600 index. Share price declines across the sector were prompted by U.S. President Donald Trump, who sent letters on Thursday to 17 major pharmaceutical firms, including Novo Nordisk, telling them to cut drug prices in the United States. Novo Nordisk on Tuesday slashed its forecast for 2025 sales growth due to competition from compounded, or copycat, versions of Wegovy and appointed veteran insider Maziar Mike Doustdar as its new CEO, prompting its shares to fall 23% on the day. Novo became Europe's most valuable listed firm after launching Wegovy in June 2021, worth some $650 billion in the middle of last year. But its shares have lost more than two-thirds since on concerns the drugmaker is losing ground in the obesity drug race. Its market cap is now $214.5 billion. "The U.S. healthcare system is complex, but Novo Nordisk will continue to work to find solutions that help people access the medicines they need at affordable prices," Novo said in an emailed statement. Novo's shares were around 2% lower at 1453 GMT, bringing this week's losses to around 30% - the stock's worst week ever. The European healthcare index was down around 1% to its lowest since April. "Trump doesn't have the mandate to tell Novo Nordisk how to price their products in the U.S., but investors are just panicking about the risk of another downgrade," said Nordnet analyst Per Hansen. The pressure to lower prices adds to Novo's problems in the United States, its biggest market. It faces competition from Eli Lilly and from compounders - custom-made medicines that are based on the same ingredients as branded drugs. "This is a repricing of the obesity market, it's a repricing of the United States as the world's most attractive drug market, and it's a repricing of the risk from Donald Trump," Hansen said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
The Hill
a day ago
- The Hill
New tariffs could raise prices of Ozempic, Wegovy
(NEXSTAR) – A trade deal between the U.S. and the European Union is expected to impose a 15% tax on pretty much all goods imported from Europe, from fancy French wines to sleek German cars and in-demand pharmaceuticals. Some of the most recognizable brand names that could be impacted include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to treat diabetes and promote weight loss. Both are made by Novo Nordisk, a Danish company. But the European drugs are extremely popular here in the U.S. Wegovy – the version of the drug that's FDA-approved to treat obesity – has about 200,000 weekly prescriptions in the U.S., according to Novo Nordisk. Even before the new tariffs, many people have found the medications to be prohibitively expensive. Without insurance, they cost about $500 a month. What is the Presidential Fitness Test? It's usually cheaper for those who can get the drug covered by their health plan. Novo says of its patients who have coverage in the U.S., 85% pay $25 or less per month. After the tariffs take effect, the prices of importing these medications into the U.S. will go up, but who will pay that tax isn't straightforward. Rena Conti, an associate professor at Boston University's Questrom School of Business, told NBC News that drug companies could just raise their price list right away to offset the higher cost. Those without insurance might notice the sticker price change, but those with coverage could end up paying more in higher premiums. 'The big picture is: The cost of imported drugs is about to become more expensive for all Americans,' Joe Brusuelas, principal and chief economist for RSM US, said in an interview with Axios. Other name-brand drugs like Botox, Viagra and Keytruda (a cancer medication) are also manufactured in Europe and impacted by the tariffs. Some drug generics were supposed to be carved out of the deal, but details were still pending as of Thursday. When asked how Ozempic and Wegovy would be impacted by the new 15% tariff, a Novo Nordisk spokesperson told Nexstar the company 'remains focused on improving patient access and affordability, and we will continue to work to find solutions that help people access the medication they need.'
Fox News
2 days ago
- Fox News
Banned chemicals found in American shampoo, sunscreen and tampons across major brands
From shampoo and sunscreen to tampons, many personal care products on American shelves contain chemicals linked to cancer, infertility, and hormone disruption—ingredients that are banned or restricted in the European Union and other countries. Despite these alarming associations, no federal law in the U.S. requires companies to disclose potentially harmful ingredients. Only California mandates limited transparency, leaving most Americans in the dark about what they're putting on—and absorbing into—their bodies. For Tiah Tomlin-Harris, a two-time survivor of triple-negative breast cancer, that lack of transparency was a wake-up call. Diagnosed before age 40 with no genetic predisposition, Tomlin-Harris began asking hard questions: Where is this coming from? Genetic testing came back negative, placing her among the 80–90% of breast cancer patients whose illness isn't linked to family history. Her background as a chemist in the pharmaceutical industry gave her a unique perspective—and a critical eye for labels. "I started to dig into the causations," she told FOX. "The first thing I did was remove every single product in my house—from hair care to dish detergent. I went back to grandma's remedies—baking soda, vinegar—because I didn't know what was safe anymore." As she researched, she realized just how many widely used beauty and hygiene products are packed with potentially harmful chemicals. While Health and Human Services Secretary Robert F. Kennedy Jr. has pushed for the removal of toxic additives in processed foods, he has yet to tackle the personal care industry. FDA Commissioner Marty Makary admits the agency is in a "deregulatory mindset," saying, "[We've] been regulating too much." That mindset has led to an explosion of consumer-driven tools like Yuka and Clearya, apps that scan barcodes and analyze ingredient safety using AI. "Most people are shocked," said Julie Chapon, Yuka's co-founder. "They assume green packaging means safety." Tomlin-Harris emphasized the disproportionate impact on women of color, particularly Black women. "We spend nine times more on beauty products than any other demographic, yet these products often contain the most harmful ingredients—parabens, phthalates, formaldehyde, benzene. These aren't just linked to cancer. They're weakening chemotherapy drugs. They're disrupting hormones. They're impacting fertility—for men and women." A Consumer Reports investigation found carcinogens in 10 of the top braiding hair brands, many of which are marketed to Black women and girls. Janet Nudelman, Director of the Campaign for Safe Cosmetics at Breast Cancer Prevention Partners, agrees that consumers are often left choosing "between protecting against skin cancer versus increasing their risk of breast cancer" because of harmful ingredients. Dr. Leonardo Trasande, whose studies highlight the health hazards of common chemicals, called the current system "rigged to produce chemical exposures that are toxic to our hormones." The consequences, he warns, are societal: higher healthcare costs and lifelong reproductive and developmental health problems. The federal government is slowly responding. The Safer Beauty Bill package, reintroduced in Congress, seeks to ban toxic ingredients, increase ingredient disclosure and protect vulnerable populations like hairstylists, nail technicians, and women of color. But for now, consumers are largely left to protect themselves. FDA Commissioner Makary insists change is coming: "We're doing an inventory of all chemicals in the food supply to see how we can make it safer." Still, advocacy groups say the U.S. is far behind the EU in regulating cosmetic safety. Industry representatives push back. The Personal Care Products Council asserts: "PCPC and our member companies are fully committed to upholding the highest standards of safety, quality and transparency." But for advocates like Tomlin-Harris, promises aren't enough. "This isn't just a women's issue," she said. "It's a people's issue. Men are affected. Children are affected. Our entire population is being exposed to chemicals we didn't consent to, and we're paying the price." Her message is clear: "We need transparency. We need regulation. And we need accountability from the companies creating these products. It's time to detox our routines, demand safer alternatives and prioritize our health."
